Shorter treatment for drug-resistant tuberculosis
Part of Infections, Lungs & breathing clinical trials.
This study tests a shorter treatment for a type of TB that is resistant to rifampicin (a common TB medicine) but still sensitive to isoniazid. It aims to see if this shorter regimen is as effective as the current longer one, potentially making treatment less burdensome for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of pulmonary tuberculosis (TB) affecting the lungs
- Your TB bacteria must be resistant to rifampicin (or you cannot take rifampicin, such as due to side effects or drug interactions) and must be sensitive to isoniazid
- You must be 18 years or older
- You must be willing to take oral medication and follow the study schedule
- You must not be pregnant or breastfeeding, and if you are of childbearing age, you agree to use effective contraception
- You must not have a serious allergy to fluoroquinolone antibiotics (like moxifloxacin or levofloxacin) or have significant liver problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a higher dose of the antibiotic rifampicin can shorten tuberculosis treatment from 6 months to 4 months. If you have drug-sensitive TB, this could mean fewer months of medication and fewer side effects.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This trial tests a shorter treatment for tuberculosis (TB) using a combination of three medicines: bedaquiline, moxifloxacin, and pyrazinamide. If you have TB in your lungs, this could be a way to treat it more quickly than the standard longer course.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
This trial tests whether a shorter treatment using the drug rifampicin is as good as the usual longer treatment for people with less severe tuberculosis (TB). If you join, you'd get a shorter course of pills, which might be more convenient and have fewer side effects.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.